Retatrutide vs Tirzepatide.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease. It is a single synthetic peptide engineered to act as a "triple G" agonist, simultaneously stimulating three nutrient-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from the single agonist semaglutide (GLP-1) and the dual agonist tirzepatide (GIP/GLP-1), both already approved.

Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).

Retatrutide is a balanced agonist at three receptors, each contributing a distinct metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite and food intake. GIP receptor agonism further modulates insulin response and appears to improve nutrient handling and tolerability. The defining addition is glucagon receptor agonism, which raises hepatic glucose output and, importantly, increases energy expenditure and promotes hepatic lipid oxidation/mobilization. The combination is intended to layer glucagon-driven increases in energy expenditure and reductions in liver fat on top of the appetite suppression and glycemic benefits of incretin (GLP-1/GIP) signaling. Because glucagon agonism can raise hepatic glucose production and resting heart rate, the receptor balance and dose are designed to keep net effects metabolically favorable.

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.

Human evidence comes from a completed Phase 2 program and emerging Phase 3 data, so this is no longer animal-only, though long-term outcome and safety data remain immature. In the 48-week Phase 2 obesity trial (Jastreboff et al., NEJM 2023), adults with obesity/overweight without diabetes had least-squares mean weight reductions of roughly -17.1%, -22.8%, and -24.2% across higher dose groups versus -2.1% with placebo. A parallel Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) showed substantial reductions in HbA1c and body weight. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) reported large relative reductions in liver fat, with the majority of higher-dose participants reaching liver fat below the steatosis threshold. In May 2026 Lilly reported topline Phase 3 results (TRIUMPH-1, ~2,339 adults), with the highest dose producing about 28.3% mean weight loss at 80 weeks; full peer-reviewed Phase 3 publications and the broader TRIUMPH cardiovascular/diabetes outcome trials were still pending at that time.

Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.

In trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related, mostly mild to moderate, and concentrated during dose escalation; using a lower starting dose partially mitigated them. A mechanistically important signal is a dose-dependent increase in heart rate, which in the Phase 2 obesity trial peaked around 24 weeks before declining; glucagon receptor agonism also raises hepatic glucose output, requiring monitoring. Phase 3 topline data showed dose-dependent discontinuation due to adverse events. Because retatrutide is investigational, its long-term safety, cardiovascular outcomes, and effects in broad real-world populations are not yet established. Compounded, "research-use-only," or gray-market retatrutide is not quality-controlled and carries additional, unquantified risks.

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.

As of mid-2026 retatrutide is investigational and not approved by the FDA, EMA, MHRA, or any other regulator for any indication; it remains in Phase 3 development (the TRIUMPH program) by Eli Lilly. It is not a dietary supplement and any product sold as "research-use-only" retatrutide is unapproved.

Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.